Condition deep-dive · 6 min read

Dry eye supplement protocol — what omega-3 and the rest of the evidence shows

Updated 2026-05-10 · Reviewed by SupplementScore editors · No sponsorships

Dry eye disease (DED) ranges from intermittent screen-related discomfort to debilitating evaporative or aqueous-deficient disease that impairs vision and daily function. The supplement evidence here has a complicated arc: smaller positive trials supported omega-3 EPA/DHA in DED, the large NIH-funded DREAM trial (n=535) found no significant benefit over olive oil placebo at 12 months, and subsequent reanalyses by subgroup have nuanced the picture rather than overturned it. The honest read: omega-3 may help selected DED phenotypes (especially evaporative / meibomian gland dysfunction-driven), but the headline-grabbing improvements in early small trials do not generalise.

Read this first. DED has multiple subtypes (aqueous-deficient, evaporative, mixed) with different management. Persistent or worsening symptoms deserve ophthalmology evaluation — particularly to rule out underlying autoimmune disease (Sjögren's syndrome), to identify treatable causes (medication-induced, hormone-related, blepharitis), and to consider prescription therapies (cyclosporine, lifitegrast, varenicline nasal spray, autologous serum tears) that often outperform supplements when DED is moderate or worse.

What actually has trial evidence

Tier 2 evidence · Mixed; subgroup signal in evaporative DED

Omega-3 (EPA/DHA, with the DREAM caveat)

2–4 g EPA+DHA/day combined; 3 months minimum trial

Several positive RCTs in DED at lower doses (1–2 g/day) preceded the DREAM trial. DREAM (Asbell 2018, n=535, 12 months) found no significant difference between 3 g/day EPA+DHA and olive oil placebo on the primary OSDI endpoint. Subgroup analyses suggest the placebo (olive oil) may not have been truly inert and that meibomian gland dysfunction-predominant patients might respond better than aqueous-deficient patients. Reasonable as a 3-month trial in evaporative DED, with a clear stopping rule if no symptomatic improvement. Discuss with prescriber if on anticoagulants.

Tier 2 evidence · Sjögren's-related DED

Vitamin D3 (in confirmed deficiency)

2,000–4,000 IU/day to a 25-OH-D target of 30–50 ng/mL

Vitamin D deficiency is more common in DED cohorts than in matched controls, particularly in Sjögren's-related DED. Small interventional trials show modest improvements in DED symptoms with correction of deficiency. Test 25-OH-D first; supplement to a target. Effect on DED specifically is modest.

Tier 3 evidence · Anti-inflammatory adjunct

Curcumin (bioavailable form)

500 mg b.i.d. of a bioavailable curcumin (phytosome, BCM-95, or similar)

Limited DED-specific RCT evidence; some small trials in DED with overlapping inflammatory components have shown symptomatic improvement. Plausible mechanism via NF-κB-mediated cytokine modulation. Bioavailability of native curcumin is poor; phytosome formulations are necessary for any meaningful systemic exposure. Discuss with prescriber if on anticoagulants.

The lifestyle and environment base — usually higher yield than supplements

Several modifiable inputs typically produce larger improvements than any oral supplement:

20-20-20 screen rule — every 20 minutes look 20 feet away for 20 seconds; reduces blink rate suppression that drives screen-related DED.
Lid hygiene — warm compresses (10 minutes b.i.d.) and gentle lid massage, particularly for meibomian gland dysfunction.
Humidification — bedroom humidifier at 40–60% relative humidity; meaningful improvement in symptoms, particularly during heating season.
Preservative-free artificial tears — first-line symptomatic relief; preservative-free formulations are appropriate for use more than 4× daily.
Reduced wind / fan exposure — direct fan or air-conditioning vents at the face dramatically increase tear evaporation.
Medication review — antihistamines, antidepressants, oral contraceptives, isotretinoin, and many others contribute to DED; review with prescribers.

What to skip

"Eye health" combination products with bilberry and various honourable mentions — the evidence base is thin and the AREDS2 framework is not the right reference here (AREDS2 is for AMD, not DED).
Mega-dose vitamin A retinol oral supplementation — vitamin A is essential for tear film integrity but routine megadose oral supplementation is hepatotoxic. Topical retinol-containing products marketed for the periocular area are a different story; oral high-dose vitamin A is not the answer.
Generic flax oil as omega-3 substitute — flax is rich in ALA, which converts poorly to EPA/DHA in humans; the DED trials used preformed EPA/DHA from fish or algal oils.
"Tear gland repair" supplements with stem-cell-promoting claims — not supported by clinical trial evidence in DED.
Cannabis / CBD products marketed for dry eye — cannabis use is independently associated with worse DED symptoms; CBD has no DED-specific evidence.

What to track

The Ocular Surface Disease Index (OSDI) is the standard validated DED self-report tool — 12 items, takes about 5 minutes. The minimum clinically important difference is approximately 7 points. Pair OSDI with subjective symptom severity (frequency of artificial tear use, screen time tolerance, end-of-day symptom intensity). Reassess at 12 weeks of any supplement intervention. If OSDI hasn't improved at 12 weeks, the supplement is not the rate-limiting step.

Practical quick-start. Optimise the lifestyle and environment base first — preservative-free artificial tears + warm compresses + 20-20-20 screen rule + bedroom humidifier. Test 25-OH-D and supplement to target if deficient. If DED is meibomian gland dysfunction-predominant or evaporative pattern: omega-3 EPA+DHA 2–4 g/day for a 3-month trial with clear OSDI tracking. Escalate to ophthalmology if symptoms remain moderate-to-severe.